Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

8 results
Display

Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer

Nam CH, Koh J, Ock CY, Kim M, Keam B, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS

Background/Aims: Programmed death-ligand 1 (PD-L1) expression, a validated predictive biomarker for anti-PD-1/PD-L1 inhibitors, is reported to change over time. This poses challenges during clinical application in non-small cell lung cancer. Methods:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Programmed Death Ligand 1 Immunohistochemistry in TripleNegative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability

Purpose: The programmed death ligand 1 (PD-L1) SP142 assay with a 1% immune cell (IC) cutoff is approved for the selection of advanced triple-negative breast cancer (TNBC) patients for atezolizumab...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Human Rhinovirus Infection Enhances the Th2 Environment in Allergic and Non-allergic Patients with Chronic Rhinosinusitis

Ko YK, Zhang YL, Wee JH, Han DH, Kim HJ, Rhee CS

Objectives. This study was conducted to determine whether patients with allergic rhinitis might be more susceptible to human rhinovirus (HRV) infection and whether the effects of infection on the elicited...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients

Park W, Bang JH, Nam AR, Jin MH, Seo H, Kim JM, Oh KS, Kim TY, Oh DY

Purpose The soluble form programmed death-ligand 1 (sPDL1) has immunosuppressive properties and is being studied as a candidate biomarker for immuno-oncology drug development. We measured the serum sPDL1 at pre-and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Concordance of Programmed DeathLigand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer

Lee SE, Park HY, Lim SD, Han HS, Yoo YB, Kim WS

Purpose: Triple-negative breast cancer (TNBC) represents a major clinical challenge due to its aggressive and metastatic behavior and the lack of available targeted therapies. Therefore, therapeutic strategies are needed to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma

Iijima M, Okonogi N, Nakajima N, Morokoshi , Kanda H, Yamada T, Kobayashi , Banno K, Wakatsuki , Yamada S, Kamada T, Aoki D, Hasegawa S

OBJECTIVE: Programmed cell death-ligand 1 (PD-L1) is expressed in tumor cells and has been shown to predict clinical outcomes of several types of malignancies. The aim of this study was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer

Kim SJ, Kim S, Kim DW, Kim M, Keam B, Kim TM, Lee Y, Koh J, Jeon YK, Heo DS

PURPOSE: The purpose of this study was to evaluate the relationships between the resistance of anaplastic lymphoma kinase (ALK)‒positive non-small cell lung cancer (NSCLC) to ALK inhibitors and the programmed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
miR-195/miR-497 Regulate CD274 Expression of Immune Regulatory Ligands in Triple-Negative Breast Cancer

Yang L, Cai Y, Zhang D, Sun J, Xu C, Zhao W, Jiang W, Pan C

PURPOSE: Immune suppression is common in patients with advanced breast cancer but the mechanisms underlying this phenomenon have not been sufficiently studied. In this study, we aimed to identify B7...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr